Physician Assistant in Salida, CO Accepting Medicare

9 Physician Assistant nurses found. Showing 1 - 9

Mrs. Hannah Pierce, PA-C Physician Assistant - Medical Medicare: Medicare Enrolled Practice Location: 515 E 1st St, Salida, CO 81201 Phone: 877-345-5300

Carol P Johnson, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 1000 Rush Dr, Salida, CO 81201 Phone: 719-530-2048    Fax: 719-530-2055

Ms. Donna Sheree Beddingfield, PA-C Physician Assistant - Medical Medicare: Accepting Medicare Assignments Practice Location: 925 Rush Dr, Salida, CO 81201 Phone: 719-539-4600    Fax: 719-539-4629

Karli Jacobson, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 550 W Hwy 50, Salida, CO 81201 Phone: 719-530-2020    Fax: 719-530-2021

Jamie Vollmerhausen, P.A.C. Physician Assistant Medicare: Medicare Enrolled Practice Location: 910 Rush Dr, Salida, CO 81201 Phone: 719-539-6637

Charlotte S Karls, PA-C Physician Assistant - Medical Medicare: Medicare Enrolled Practice Location: 910 Rush Dr, Salida, CO 81201 Phone: 719-539-6637    Fax: 719-539-5275

Beth Pack, PA Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 550 W Hwy 50, Salida, CO 81201 Phone: 719-539-2048    Fax: 719-539-2055

Aubrey Danell Pavlacka, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 1000 Rush Dr, Salida, CO 81201 Phone: 719-530-2200

Ms. Jennifer E Lee, P.A. Physician Assistant Medicare: Medicare Enrolled Practice Location: 910 Rush Dr, Salida, CO 81201 Phone: 719-539-6637    Fax: 719-539-2364

News Archive

To avoid metabolic syndrome is relatively simple – 30 minutes of physical activity once a week

Metabolic syndrome is a condition that is affecting thousands of Canadians and is putting them at risk of heart disease and stroke, especially those aged 50 and over.

Catalyst Pharmaceutical Partners, NIDA to jointly conduct Phase II(b) trial of CPP-109 for cocaine addiction

Catalyst Pharmaceutical Partners, Inc. announced today that it has signed a definitive Clinical Trial Agreement (CTA) with the National Institute on Drug Abuse (NIDA) to jointly conduct a U.S. Phase II(b) clinical trial evaluating CPP-109, Catalyst's formulation of vigabatrin, for the treatment of cocaine addiction. As part of the CTA, NIDA, under their agreement with Veteran's Administration Cooperative Studies Program, will provide substantial resources for the estimated $10 million trial cost.

Research shows even mild to moderate kidney disease may diminish child's quality of life

Challenging prevailing wisdom that only children with end-stage kidney disease suffer physical, social, emotional and educational setbacks from their disease, research led by Johns Hopkins Children's Center shows that even mild to moderate kidney disease may seriously diminish a child's quality of life.

RMEI, PIM jointly sponsor virtual lecture to address the need for education on ALL in AYAs

Currently, no definitive standard of care exists for adolescent and young adults (AYA) with acute lymphoblastic leukemia (ALL). Recent research suggests that AYAs treated with pediatric treatment protocols have better outcomes than those treated with adult treatment protocols.

Read more Medical News

› Verified 1 days ago